Count | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 46 | |
| 5 | |
| 1 | |
| 2 | |
| 4 | |
| 1 | |
| 5 | |
| 1 | |
| 18 | |
| 2 | |
| 2 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 14 | |
| 14 | |
| 2 | |
| 1 | |
| 5 | |
| 1 | |
| 5 | |
| 4 | |
| 1 | |
| 1 | |
| 2 | |
| 4 | |
| 1 | |
| 3 | |
Interferon Type I, Recombinant/administration & dosage/*pharmacology | 3 |
| 1 | |
Interferon Type I/administration & dosage/blood/*pharmacokinetics | 1 |
Interferon Type I, Recombinant/administration & dosage/immunology | 1 |
Natriuretic Peptide, C-Type/administration & dosage/*pharmacology | 1 |
Angiotensin II Type 1 Receptor Blockers/*administration & dosage | 1 |
| 1 | |
| 2 | |
| 2 | |
Interferon Type I, Recombinant/administration & dosage/*therapeutic use | 1 |
Interferon Type I, Recombinant/administration & dosage/therapeutic use | 1 |
Interferon Type I, Recombinant/*administration & dosage/adverse effects | 1 |
| 3 | |
| 1 | |
| 1 | |
| 29 | |
| 156 | |
| 16 | |
| 2 | |
| 5 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 59 | |
| 2 | |
| 16 | |
| 3 | |
| 2 | |
| 24 | |
| 1 | |
| 2 | |
| 1 | |
| 3 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |